(AOF) – The board of directors of Affluent Medical, a French MedTech player founded by Truffle Capital, wishes to accelerate its deployment. To this end, it has decided to adapt its method of governance by separating the functions of Chairman of the Board of Directors and Chief Executive Officer. Consequently, Sébastien Ladet joins the company as Chief Executive Officer as of today and Michel Finance is maintained in his role as Chairman of the Board of Directors.
Sébastien Ladet, Ph.D. began his career in the R&D department of Medtronic in France (formerly Covidien), where he held several positions of responsibility in the development of innovative technologies applied to new implantable medical devices with a view to their marketing.
In 2016, he became Director of Strategy and R&D Portfolio Management for Medtronic’s Hernia and Hemostasis business in the United States. In 2020, he was promoted to Senior R&D Director – Technology Strategy and Innovation of the Surgical Innovation Business Unit (6 billion US dollars in revenue).
Michel Finance will continue his mandate as Chairman of the Board of Directors and will retain executive functions at the same time until the end of the year to support the transition and provide general management with the benefit of his experience in the deployment of growth strategies. in several listed companies in the health sector.
In addition, Michel Therin joins the company’s board of directors as of this day, replacing Daniel Hayoz who becomes censor. Michel Therin benefits from extensive experience in the definition and implementation of Medtech deployment strategies at the international level. Former President of Siemens Healthineers – Innovative Therapies. He also spent more than 10 years at Medtronic as US and France Vice President, in charge of the development and commercialization of innovative surgical devices.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address email@example.com OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.